How Overweight Do You Need to Be for Mounjaro?

What BMI do you need, and does a health condition change the number?

The licensed eligibility for tirzepatide in the UK sets two entry points. A BMI of 30 or above on its own is sufficient. Drop below that to a BMI of 27 or above and you can still qualify, provided you have at least one weight-related comorbidity, conditions that count include type 2 diabetes, prediabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea, and osteoarthritis, among others.

So the question of how overweight you need to be for Mounjaro does not have a single fixed answer. It depends on whether a qualifying health condition is in the picture. Someone with a BMI of 28 and well-controlled hypertension may be eligible; someone with the same BMI and no weight-related conditions may not be. A prescriber weighs both together.

Background also matters. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, UK clinical guidance recognises that health risks associated with excess weight tend to arise at lower BMI values. Thresholds are therefore typically 2.5 kg/m² lower for those groups, so BMI 27.5 may be the relevant upper threshold, with 24.5 the lower one where a comorbidity is present. The specific BMI figures that apply to Mounjaro are worth reading through if you are close to any of these numbers. You can check your own BMI using the NHS BMI calculator.

Does BMI alone decide whether you are approved?

No. The BMI thresholds define who can be considered; they do not define who will be approved. Mounjaro is a prescription-only medicine, which means a GPhC-registered prescriber must assess your full health history before any prescription is written.

At nume, that assessment is carried out by a qualified Independent Prescriber (a real clinician, not an automated system) who reads your consultation answers the same day you submit them. They look at your current medicines, relevant conditions, and anything that might make the treatment unsuitable. Certain conditions, including a personal or family history of medullary thyroid carcinoma, a history of pancreatitis, and some gastrointestinal conditions, would need careful discussion before tirzepatide could be considered.

This is the same clinical reasoning set out in the NHS's tirzepatide guidance, the prescriber's job is to establish that the benefits outweigh the risks for you specifically. Being above the BMI line opens the door; it does not walk you through it automatically.

If you want a clearer sense of where you sit before you start, the BMI ranges relevant to Mounjaro prescribing page covers this in more detail.

How does NHS eligibility differ from private eligibility?

This is where the two routes diverge sharply. Private prescribing follows the licensed SmPC thresholds described above. NHS prescribing follows NICE appraisal guidance, which is considerably more restrictive.

NICE recommended tirzepatide for NHS use in December 2024 (TA1026), but only through a phased rollout. As of mid-2026, NHS access requires a BMI of at least 35 alongside four or more of five specified conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. A second cohort, requiring BMI 35 to 39.9 and four or more conditions, became eligible in June 2026. Further phases are planned through to 2027.

Most adults with a BMI of 30 to 34 who are eligible privately will not yet meet the NHS threshold. For those people, a private route to Mounjaro is often the practical alternative, no referral, no waiting list, just a clinical assessment to establish suitability. You can also read more about the full Mounjaro prescribing picture if you are weighing up your options.

If you are close to but not quite at any threshold, the right first step is a consultation rather than guessing. Our prescribers can review your details and tell you whether treatment is appropriate. Pricing is transparent (one sum covering consultation, prescription, and free next-working-day DPD delivery in plain packaging) and the treatment options page is the place to begin.

What if you don't quite meet the threshold right now?

A common question our prescribers hear is what happens if your BMI sits just below 30 with no qualifying condition. The honest answer: tirzepatide is not licensed for that group, and a prescriber acting within UK law cannot prescribe it. The question of whether Mounjaro is accessible below the threshold is worth reading properly, because the answer matters for your safety as much as for the rules.

For people in that position, lifestyle support, dietary changes, and other weight-management options may be more appropriate starting points. Weight-loss treatment options covers the landscape if you want to see what might be available to you at your current BMI. The FAQs section also covers the most common eligibility questions in brief. If you are unsure, our team is straightforward to reach via the contact page.

Where someone does meet the eligibility criteria (BMI 30 or above, or 27 or above with a weight-related condition) a free consultation with our prescribers is the next step. Speak to our prescribers to find out where you stand.